OTC Markets OTCPK - Delayed Quote USD

Bayer Aktiengesellschaft (BAYRY)

Compare
6.76 +0.01 (+0.15%)
As of 3:00 PM EST. Market Open.
Loading Chart for BAYRY
DELL
  • Previous Close 6.75
  • Open 6.72
  • Bid 6.75 x 40000
  • Ask 6.76 x 40000
  • Day's Range 6.70 - 6.77
  • 52 Week Range 6.70 - 11.33
  • Volume 220,325
  • Avg. Volume 807,189
  • Market Cap (intraday) 26.565B
  • Beta (5Y Monthly) 0.97
  • PE Ratio (TTM) --
  • EPS (TTM) -0.35
  • Earnings Date Nov 12, 2024
  • Forward Dividend & Yield 0.03 (0.44%)
  • Ex-Dividend Date Apr 29, 2024
  • 1y Target Est 22.11

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

www.bayer.com

96,567

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BAYRY

View More

Performance Overview: BAYRY

Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

BAYRY
26.46%
DAX P
14.95%

1-Year Return

BAYRY
39.83%
DAX P
26.78%

3-Year Return

BAYRY
49.66%
DAX P
20.13%

5-Year Return

BAYRY
60.08%
DAX P
46.59%

Compare To: BAYRY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BAYRY

View More

Valuation Measures

Annual
As of 11/4/2024
  • Market Cap

    26.43B

  • Enterprise Value

    61.54B

  • Trailing P/E

    --

  • Forward P/E

    4.61

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.52

  • Price/Book (mrq)

    0.68

  • Enterprise Value/Revenue

    1.20

  • Enterprise Value/EBITDA

    5.81

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -2.69%

  • Return on Assets (ttm)

    3.71%

  • Return on Equity (ttm)

    -3.45%

  • Revenue (ttm)

    47.11B

  • Net Income Avi to Common (ttm)

    -1.27B

  • Diluted EPS (ttm)

    -0.35

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.02B

  • Total Debt/Equity (mrq)

    129.94%

  • Levered Free Cash Flow (ttm)

    6.26B

Research Analysis: BAYRY

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 11.14B
Earnings -34M
Q3'23
Q4'23
Q1'24
Q2'24
0
5B
10B
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

7.60
22.11 Average
6.76 Current
50.18 High
 

Company Insights: BAYRY

Research Reports: BAYRY

View More
  • Bayer: Litigation Headline Risk (Again); Fair Value Unchanged

    Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

    Rating
    Price Target
     
  • Bayer Earnings: Steady Growth Supported by New Drug Launches Offsetting Generic Pressures

    Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

    Rating
    Price Target
     
  • Bayer Earnings: Solid Results Aided by Litigation Win, Cost-Cutting, and Innovation Advancements

    Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

    Rating
    Price Target
     
  • Bayer Earnings: Expected Cost Pressures Lead to a Valuation Cut, but Stock Remains Undervalued

    Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm also has a crop science business that includes seeds, pesticides, herbicides, and fungicides, which was expanded through the acquisition of Monsanto.

    Rating
    Price Target
     

People Also Watch